Phio Pharmaceuticals Corp. (PHIO)
$1.13+$0.01 (+0.89%) Today
Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 3 | 35,000 | $38K |
23 Form 4 filings on record, the earliest from May 21, 2025, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Ronald Todd Plott - Director | Open-market purchase | Common Stock, $.0001 par value | 15,000 | $1.14 | $17K | |
| Robert J. Bitterman - Officer | Open-market purchase | Common Stock, $.0001 par value | 10,000 | $1.06 | $11K | |
| Robert J. Bitterman - Officer | Open-market purchase | Common Stock, $.0001 par value | 10,000 | $0.99 | $10K | |
 Curtis Lockshin - Director | Grant or award | Common Stock, $.0001 par value | 16,600 | $0.00 | - | |
| Jonathan E. Freeman - Director | Grant or award | Common Stock, $.0001 par value | 16,600 | $0.00 | - | |
| David H. Deming - Director | Grant or award | Common Stock, $.0001 par value | 23,800 | $0.00 | - | |
| Lisa Cabott Carson - Officer | Grant or award | Common Stock, $.0001 par value | 47,000 | $0.00 | - | |
 Patricia A. Bradford - Director | Grant or award | Common Stock, $.0001 par value | 18,500 | $0.00 | - | |
| Robert J. Bitterman - Officer | Grant or award | Common Stock, $.0001 par value | 120,000 | $0.00 | - | |
| Robert J. Bitterman - Officer | Open-market purchase | Common Stock, $.0001 par value | 5,000 | $1.03 | $5K | |
| Robert J. Bitterman - Officer | Open-market purchase | Common Stock, $.0001 par value | 5,000 | $1.02 | $5K | |
| Robert J. Bitterman - Officer | Open-market purchase | Common Stock, $.0001 par value | 5,000 | $1.14 | $6K | |
| Robert J. Bitterman - Officer | Open-market purchase | Common Stock, $.0001 par value | 5,000 | $1.27 | $6K | |
| Robert J. Bitterman - Officer | Tax withholding / forfeiture | Common Stock, $.0001 par value | 4,111 | $2.32 | $10K | |
| Robert J. Bitterman - Officer | Grant or award | Common Stock, $.0001 par value | 250,000 | $0.00 | - | |
| Lisa Cabott Carson - Officer | Grant or award | Common Stock, $.0001 par value | 47,000 | $0.00 | - | |
| Jonathan E. Freeman - Director | Grant or award | Common Stock, $.0001 par value | 14,700 | $0.00 | - | |
| Robert L. Ferrara - Director | Grant or award | Common Stock, $.0001 par value | 23,100 | $0.00 | - | |
| Curtis Lockshin - Director | Grant or award | Common Stock, $.0001 par value | 16,200 | $0.00 | - | |
| Patricia A. Bradford - Director | Grant or award | Common Stock, $.0001 par value | 18,800 | $0.00 | - | |
| David H. Deming - Director | Grant or award | Common Stock, $.0001 par value | 14,000 | $0.00 | - | |
| Robert J. Bitterman - Officer | Open-market purchase | Common Stock, $0.0001 par value | 2,000 | $2.42 | $5K | |
| Robert J. Bitterman - Officer | Open-market purchase | Common Stock, $0.0001 par value | 1,500 | $2.75 | $4K | |
| Robert J. Bitterman - Officer | Open-market purchase | Common Stock, $0.0001 par value | 3,000 | $1.77 | $5K | |
| Robert J. Bitterman - Officer | Open-market purchase | Common Stock, $0.0001 par value | 1,200 | $1.78 | $2K |
Phio Pharmaceuticals Corp. (PHIO) had 3 insider filings in the last 90 days, with the most recent on 2026-08-20. The full record for PHIO runs to 23 Form 4 filings, the earliest from 2025-05-21. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
3 insider purchases of PHIO were filed in the last 90 days, totaling $38K.
No insider sales of PHIO were filed in the last 90 days.
This page tracks PHIO Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add PHIO to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
